ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB094

Single Centre Study Identifying the Impact of COVID-19 on Patterns of Bacteremia in Patients on Haemodialysis

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Cleasby, Charlotte, St Helier Hospital, Carshalton, England, United Kingdom
  • Sivakumaran, Priya, St Helier Hospital, Carshalton, England, United Kingdom
  • Makanjuola, David, St Helier Hospital, Carshalton, England, United Kingdom
Background

Haemodialysis (HD) patients have an increased risk of death due to bacteraemia; with central venous catheters for dialysis, being a key risk factor. The coronavirus-19 (COVID -19) pandemic further accelerated mortality and morbidity rates in these patients, partly due to co-morbidities and regular hospital visits for dialysis. We analysed the prevalence of bacteraemias in HD patients between 2019-2024, specifically assessing type and source of organism, and antibiotic resistance.

Methods

HD patients with a bacteraemia between 2019-2024 were identified from the Microbiology and Renal databases. Data included causative organism, antibiotic sensitivity, type of HD access, source of bacteraemia and patient outcome. Contaminants and repeat positive cultures within the space of one week which grew the same organism were excluded from the analyses.

Results

Prevalence of organisms
423 bacteraemias were recorded, of which 177 were not repeats, or contaminants. 74% were line associated, 2% were from AV fistulae, the rest were from other sources e.g osteomyelitis.
72.8% were Gram positive, 24.2% were Gram negative and 0.2% were fungi. There was an increased number of bacteraemias in 2020 and 2021, and the prevalence of Enterococci was greatest in 2020.
Of the Gram positives, 40.6% were coagulase positive, 43.7% were coagulase negative, and 9.3% were enterococci. In Gram positive organisms, apart from one case of Microbacterium sp., Vancomycin resistance was only seen with enterococci, of which 58% were Vancomycin resistant.

Conclusion

We found an increase in bacteraemias in 2020-2021. It coincided with the start of the pandemic. It is not clear whether/if this was related to COVID-19, but it is interesting to see that it settled over the next two years back towards ‘baseline’. This would have been around the time that COVID vaccination was being rolled out, and the dialysis patients, in view of being in the vulnerable group, were given priority for this.
Vancomycin is the empirical antibiotic of choice for Gram positive organisms in our unit and 91% of Gram positive isolates were Vancomycin sensitive. The ‘spike’ in VREs in 2020 highlights the importance of anti-microbial stewardship and continued surveillance to detect development of resistance in order to adjust anti-microbial guidelines if needed.

Digital Object Identifier (DOI)